ライフサイエンスコーパス: peptidomimetic

1 th c(RGDfK), a well-studied integrin-binding peptidomimetic.

2 ne and side chain torsion angles for a model peptidomimetic.

3 ning and refining therapeutically-attractive peptidomimetics.

4 al properties of this peptide by introducing peptidomimetics.

5 tives are valuable pharmacological agents as peptidomimetics.

6 e introduced as the backbone modification in peptidomimetics.

7 nthesis of biologically active molecules and peptidomimetics.

8 advantage of peptoids over other families of peptidomimetics.

9 ess to obtain the linear C-hydroxyalkylamido peptidomimetics.

10 synthesized and assayed libraries of mutant peptidomimetics.

11 n the design of conformationally constrained peptidomimetics.

12 chromenopyridine fused thiazolino-2-pyridone peptidomimetics.

13 ential applications in the field of peptides/peptidomimetics.

14 lent opportunity to construct small-molecule peptidomimetics.

15 development of new small antiviral drugs or peptidomimetics.

16 ioisostere to provide protease resistance in peptidomimetics.

17 rious ligands including TRP/NTL peptides and peptidomimetics.

18 We have previously described opioid peptidomimetic, 1, employing a tetrahydroquinoline scaff

19 A tetrazole-based peptidomimetic 2 (BMS-317180) was discovered as a human

20 deprotection provided the epoxide-containing peptidomimetics, 4 and 5.

21 Bicyclic peptidomimetic 7 and spirobicylic peptidomimetic 8 enhan

22 Bicyclic peptidomimetic 7 and spirobicylic peptidomimetic 8 enhanced the binding of [3H] N-propylno

23 This can be exploited by the BH3 peptidomimetic ABT737, through non-BCL-2-dependent synth

24 A peptidomimetic ADAM8 inhibitor, BK-1361, designed by str

25 lphavbeta3)) and microbubbles coupled to the peptidomimetic agent c(RGDfK) (MB(cRGD)).

26 Hsp90 targeting using a cell-permeable peptidomimetic agent resulted in marked attenuation of n

27 l pain conditions and to test potency of the peptidomimetic agonists in vivo, we evaluated these agon

28 All peptidomimetic agonists stimulated PAR(2)-dependent in v

29 y of conformationally restrained dipeptides, peptidomimetics, alkaloids, and other biologically activ

30 Mice treated with the SOCS1 peptidomimetic also exhibited reduced kidney leukocyte r

31 coated either with an alphavbeta3-selective peptidomimetic, an alpha5beta1-selective peptidomimetic,

32 To test this hypothesis, peptidomimetic analogues 3-5, which have either an N-hyd

33 We now report four peptidomimetic analogues, compounds 6-9, which are ratio

34 mbly of a diverse collection of silane-based peptidomimetic analogues.

35 ign is important for the development of this peptidomimetic and for its anti-angiogenic effects.

36 is for developing gp120 dual inhibitors into peptidomimetic and increasingly smaller molecular weight

37 Aspartic protease inhibitors (peptidomimetic and natural product), calpain inhibitors,

38 ovides structural rigidity within the cyclic peptidomimetic and promotes the creation of a stabilizin

39 458 binding was saturatable, displaceable by peptidomimetic and small molecule gamma-secretase inhibi

40 hput synthesis of linear C-hydroxyalkylamido peptidomimetics and beta-turn cyclic peptidomimetics via

41 es a concrete basis for the design of potent peptidomimetics and nonpeptidic compounds to inhibit MLL

42 The peptidomimetics and pyrimidoindolones bind to both activ

43 -HIV-1 drug target and may help in designing peptidomimetics and small molecule drugs targeted to thi

44 derived from the C-terminal tail of FGF23 or peptidomimetics and small-molecule organomimetics of the

45 cellular uptake in cancer cells by designed peptidomimetics and suggest that cancer cells with certa

46 of rhodesain inhibitors, including peptidic, peptidomimetic, and nonpeptidic structures, emphasizing

47 ional active site and allosteric inhibitors, peptidomimetics, and novel proteolysis-targeted chimera

48 phoma, can be targeted with the bisaryl urea peptidomimetic antagonist 1 (LLP2A).

49 n selectively targeted with the bisaryl urea peptidomimetic antagonist 1.

50 Structural optimization of a peptidomimetic antagonist of formyl peptide receptor 2 (

51 resent good candidates for further design of peptidomimetic antagonists capable of blocking the fusio

52 Herein, we describe a peptidomimetic approach that increases the stability of

53 etion (ADME) profile while being devoid of a peptidomimetic architecture.

54 Non-natural antimicrobial peptidomimetics are an ideal example of this, as they ha

55 Peptidomimetics are classes of molecules that mimic stru

56 Thiazolino fused 2-pyridone peptidomimetics are of significant biological importance

57 Peptidomimetics are small protein-like molecules designe

58 ligohydrazide (azatide) fragments into their peptidomimetic arms to reduce hydrophobicity and increas

59 ion toward the design of cyclic peptides and peptidomimetics as calpain inhibitors.

60 nactive peptide, administration of the SOCS1 peptidomimetic at either early or advanced stages of dia

61 fluoromethyl aldimines, small psi[CH(CF3)NH]-peptidomimetic backbones can be achieved in which a new

62 zed, and pharmacologically characterized new peptidomimetics based on a PLEV tetrapeptide scaffold de

63 CB-TE1A1P-PEG4-LLP2A), a high-affinity VLA-4 peptidomimetic-based radiopharmaceutical, was evaluated

64 crown-6 (18C6) affinities of nine protonated peptidomimetic bases are determined using guided ion bea

65 tics for neutral and protonated 18C6 and the peptidomimetic bases, as well as the proton bound comple

66 tests the hypothesis that the conjugation of peptidomimetic beta-secretase inhibitors with a fragment

67 olds that are structurally distinct from the peptidomimetic BIIE0246.

68 proapoptotic agent bone metastasis-targeting peptidomimetic (BMTP-11) in preclinical models of primar

69 nalyses revealed that the most potent cyclic peptidomimetic bound to the iNOS binding site of SPSB2 w

70 ERG inhibitory peptides (EIPs) and derived peptidomimetics bound ERG with high affinity and specifi

71 ionally restricted beta-sheet breaker hybrid peptidomimetics (BSBHps).

72 Herein, we report the synthesis of peptidomimetic building blocks containing backbone-fluor

73 viously discovered anti-alphaVbeta3 integrin peptidomimetic (c(AmpRGD)) and the clinically approved a

74 2 interaction with Plk1-PBD was blocked by a peptidomimetic called 103-8.

75 in the low micromolar range, rivaling other peptidomimetic calpain inhibitors and presenting an impr

76 meostasis, and we suggest that ANXA1 and its peptidomimetics can be novel therapeutic targets in neur

77 Since phage-borne peptidomimetics can be selected from phage display libra

78 Peptides or peptidomimetics can mimic binding of the tethered ligand

79 Peptidomimetics can respond to peptide limitations by di

80 o the surfaces and the alphavbeta3-selective peptidomimetic-coated nanotopographies promoted osteogen

81 leads to (i) a chemical library of putative peptidomimetics combining diverse azaheterocycles with t

82 This work helps address the peptidomimetic community's need for an automated and exp

83 cribe the assembly of an achiral oligo(urea) peptidomimetic compound into supramolecular helices.

84 rin extracellular fragment in complex with a peptidomimetic compound that was previously shown to par

85 r the rational design of specific and potent peptidomimetic compounds that may be useful for the trea

86 of the BCL-2 family of proteins, we designed peptidomimetic compounds using a benzoylurea scaffold to

87 nal flexibility and the peptide character of peptidomimetic compounds.

88 We introduce a family of multivalent peptidomimetic conjugates that modulate the activity of

89 Peptidomimetics containing ( S)- or ( R)-imidazolidin-2-

90 latelets are less responsive to peptides and peptidomimetics containing an arginine-glycine-aspartic

91 n Ugi four-component reaction generating the peptidomimetic core structure.

92 TTT-28, a newly synthesized thiazole-valine peptidomimetic, could reverse ABCB1-mediated MDR in vitr

93 gn and further development of small-molecule peptidomimetic CXCR4 antagonists.

94 be very valuable in the development of novel peptidomimetic CXCR4 antagonists.

95 Tyr(All) and similar residues in peptide and peptidomimetic cyclizations performed on solid phase.

96 such as PELP1 using a novel, small molecule peptidomimetic (D2).

97 se compounds may be useful in the context of peptidomimetic design of biologically relevant compounds

98 tor conformations suitable for computational peptidomimetic design, and that inclusion of disordered

99 review aims to outline useful tools towards peptidomimetic design, spanning from local modifications

100 ide isomerism with potential applications in peptidomimetic drug design and protein folding.

101 point for structure-based small molecule and peptidomimetic drug development.

102 rocyclic HIV-1 antagonists as a new class of peptidomimetic drug leads.

103 15) transport di- and tripeptides as well as peptidomimetic drugs across the cell membrane.

104 ce for the development of other peptidic and peptidomimetic drugs such as inhibitors of the blood clo

105 ts for SAR campaigns, integral components of peptidomimetic drugs, and potential drugs on their own.

106 evelopment has been complicated, as for many peptidomimetic drugs, mostly by poor drug-like propertie

107 A pyridine-enabled C-N bond activation of peptidomimetics employing cooperative palladium/copper c

108 etic and SLE model studies demonstrated that peptidomimetic FISLE-412,1 a reduced HIV protease inhibi

109 unique, selective, and potent small molecule peptidomimetic, FISLE-412, which neutralizes anti-dsDNA/

110 e mediated hydrolysis enabled preparation of peptidomimetic fluorophores with useful photophysical pr

111 dary structures is an important challenge in peptidomimetic foldamer science.

112 Peptidomimetic foldamers adopting well-defined three-dim

113 minimalist scaffold for novel stereodefined peptidomimetic foldamers and topologically biased librar

114 toids are an increasingly important class of peptidomimetic foldamers comprised of N-alkylglycine uni

115 Aliphatic N,N'-linked oligoureas are peptidomimetic foldamers that adopt a well-defined helic

116 armacology, thus prompting the design of new peptidomimetic foldamers.

117 h was followed by amino acids, peptides, and peptidomimetics for medicinal chemistry.

118 aim of using the tumor-homing cyclo[DKP-RGD] peptidomimetics for site-directed delivery of the cytoto

119 e present the synthesis of highly active RGD peptidomimetics for the alphavbeta3 integrin with remark

120 ve recently emerged as important examples of peptidomimetics for their interesting complexing propert

121 The resulting peptidomimetic formulation additives preserve the drug s

122 This peptidomimetic/free radical system is a potentially exce

123 Optimization of our previously described peptidomimetic furin inhibitors was performed and yielde

124 be potentiated by NO signaling, therefore, a peptidomimetic furoxan was tested in hippocampal slices

125 Peptidomimetics have been applied to inhibit PPIs, howev

126 Peptidomimetics have gained great attention for their fu

127 netic properties of a novel class of achiral peptidomimetic HCV NS3 protease inhibitors.

128 ethod can be used to prepare imidazole based peptidomimetics, herein exemplified by the synthesis of

129 s and provides a guide for further design of peptidomimetic HIV-1 inactivators based on the PT pharma

130 gets for anticancer therapy, and a number of peptidomimetic IAP antagonists have entered clinical tri

131 clodehydration to afford thiazole containing peptidomimetics in a short synthetic sequence.

132 ation of co-crystal structures of two potent peptidomimetics in complex with WDR5 establishes their s

133 c quantities, which can be exploited through peptidomimetics in diabetes or Alzheimer's disease.

134 h are presented to document the relevance of peptidomimetics in drug discovery.

135 g in a single process generating the desired peptidomimetics in good to excellent yields within a 25

136 ution studies of radiolabeled multi-triazolo-peptidomimetics in mice bearing receptor-positive tumor

137 ility and increased receptor affinity of the peptidomimetics in vitro.

138 On the basis of the results, a peptidomimetic inhibitor (compound 1) was designed and y

139 )(2) (2) was prepared from the nitrile-based peptidomimetic inhibitor Ac-Phe-NHCH(2)CN (1).

140 The structure of HsPDF bound to the peptidomimetic inhibitor actinonin (1.7 A) identified th

141 y demonstrated the eutomer (3S,5R)-5 to be a peptidomimetic inhibitor binding to a nonsubstrate topog

142 omplex formation and provides guidelines for peptidomimetic inhibitor design.

143 l design and development of the first potent peptidomimetic inhibitor for NTMT1/2.

144 Recently, a peptidomimetic inhibitor has entered clinical trial; how

145 east cancer cells, and targeting BCL6 with a peptidomimetic inhibitor leads to apoptosis of these cel

146 ear receptor corepressor 1 (NCoR) complex by peptidomimetic inhibitor not only significantly decrease

147 -principle, we developed a small, selective, peptidomimetic inhibitor of Ena/VASP EVH1 domain interac

148 escribe the design of a potent and selective peptidomimetic inhibitor of geranylgeranyltransferase I

149 d that zinc ion and a Michael acceptor-based peptidomimetic inhibitor synergistically inactivate FIPV

150 show that 19a is a novel potential antitumor peptidomimetic inhibitor that can be used as a starting

151 was found to be as potent as OM00-3, a known peptidomimetic inhibitor, 4-fold more selective toward b

152 e specific BCL6 inhibitor retro-inverso BCL6 peptidomimetic inhibitor-induced expression of BCL2 and

153 y to enhance the efficacy of an irreversible peptidomimetic inhibitor.

154 ing studies were conducted using a series of peptidomimetic inhibitors (compounds 1-6, Table 3) and t

155 molecular dynamics to model structures of 12 peptidomimetic inhibitors bound to the SH2 domain of STA

156 he dominant interface with small molecule or peptidomimetic inhibitors could specifically prevent act

157 Of the peptidomimetic inhibitors of APA, amastatin has higher p

158 Peptidomimetic inhibitors of HIV-1 PR are still a key re

159 pathways predictive of tumors responsive to peptidomimetic inhibitors of its 20S core protease activ

160 Peptidomimetic inhibitors of MERS-CoV 3CL(pro) were synt

161 ign, synthesis, and evaluation of reversible peptidomimetic inhibitors of Plm II as potential antimal

162 The mode of inhibition for phosphoramidate peptidomimetic inhibitors of prostate-specific membrane

163 streamlined approach for discovering potent peptidomimetic inhibitors of protein-protein interaction

164 Here, we report transmembrane peptidomimetic inhibitors of the gamma-secretase complex

165 ied the factors affecting the selectivity of peptidomimetic inhibitors of the highly homologous prote

166 have designed a class of potent macrocyclic peptidomimetic inhibitors of the menin-MLL1 interaction.

167 n, synthesis, and characterization of cyclic peptidomimetic inhibitors of the SPSB2-iNOS interaction

168 y have been exploited in discovering related peptidomimetic inhibitors of the Tat-TAR interaction in

169 A library of more than 30 macrocyclic peptidomimetic inhibitors was employed for scaffold opti

170 nd its complexes with angiotensin IV and the peptidomimetic inhibitors, amastatin and bestatin.

171 Phosphotyrosine-based peptidomimetic inhibitors, which mimic pTyr-Xaa-Yaa-Gln

172 uture structure-based design of non-covalent peptidomimetic inhibitors.

173 arbonyl pharmacophore significantly improved peptidomimetic inhibitory potency.

174 A radiolabeled peptidomimetic integrin antagonist, (111)In-DOTA-IA, was

175 ugh binding to the neonatal Fc receptor, the peptidomimetic introduces cross-species binding to cell

176 polyhydroxylated piperidine and pyrrolidine peptidomimetics is described.

177 amino acid as the central core and acting as peptidomimetics, is presented.

178 with three different classes of inhibitors: peptidomimetics, isatins, and pyrimidoindolones.

179 relationships (SAR) offer a way to establish peptidomimetic libraries.

180 r origin from the screening of combinatorial peptidomimetic library.

181 (LLP2A) is a high-affinity, high-specificity peptidomimetic ligand (inhibitory concentration of 50% =

182 ching a synthetic high-affinity and specific peptidomimetic ligand (LLP2A) against integrin alpha4bet

183 PEG4-LLP2A ([(64)Cu]-LLP2A), a high affinity peptidomimetic ligand for very late Ag-4 (VLA-4; also ca

184 rmacological delivery of a soluble ephrin-A1 peptidomimetic ligand led to a reduction in EphA2 expres

185 injection of a (64)Cu-labeled high-affinity peptidomimetic ligand referred to as (64)Cu-LLP2A, which

186 This study investigates whether CN2097, a peptidomimetic ligand which targets the synaptic scaffol

187 luated 2 conjugates of a high-affinity VLA-4 peptidomimetic ligand, LLP2A, for PET/CT imaging in a su

188 Hence, we reasoned that lipidation of peptidomimetic ligands could promote membrane targeting

189 wide variety of conformationally restricted peptidomimetic linkers at the point of juncture.

190 To efficiently design a peptidomimetic, local constraints must be introduced int

191 Peptidomimetic macrocycles have the potential to regulat

192 trategy for synthesizing passively permeable peptidomimetic macrocycles.

193 inoline scaffold and show that the resulting peptidomimetics maintain the desired pharmacological pro

194 the basis for the development of functional peptidomimetic materials responsive to external stimuli.

195 ogen receptor-coregulator interactions using peptidomimetics may be a viable therapeutic approach for

196 type of proteolytically stable FPR2-specific peptidomimetics may serve as valuable tools for future a

197 The most potent macrocyclic peptidomimetic (MCP-1), 34, binds to menin with a K(i) v

198 Evaluation of one such peptidomimetic, MM-102, in bone marrow cells transduced

199 ed drug design and optimization, macrocyclic peptidomimetic molecules bearing both a lipophilic P2 is

200 resentative of a new class of PSMA targeting peptidomimetic molecules that shows great promise as ima

201 r group chemically modified an antimicrobial peptidomimetic motif for targeted applications against c

202 lls are sensitive in vitro to ABT-263, a BH3-peptidomimetic, much more than the other tested cancer c

203 Recently, peptidomimetic N,N'-linked oligourea helices have been d

204 array comprising different types of cationic peptidomimetics obtained by a general monomer-based soli

205 We delivered dPGS-PTX in combination with a peptidomimetic of the anti-angiogenic protein thrombospo

206 The reported novel mono-triazolo-peptidomimetics of [Nle(15)]MG11 showed either improved

207 Peptoids are peptidomimetics of interest in the fields of drug develo

208 Two epoxide-containing peptidomimetics of the isopeptide, glutamyl-gamma-glutam

209 Conformationally ordered peptidomimetic oligomers are finding broad applications

210 Peptidomimetic oligomers can frequently be synthesized u

211 atility and ease of structural modification, peptidomimetic oligomers have not yet been explored exte

212 hibitors can be largely classified as either peptidomimetic or non-peptidic inhibitors.

213 lecule for the preparation of collections of peptidomimetics or biologically active compounds based o

214 ive peptidomimetic, an alpha5beta1-selective peptidomimetic, or an RGD/PHSRN peptidic molecule.

215 inal heptapeptide, P7 (Ac-1FTLDADF7) and its peptidomimetic P6 (1Fmoc(Me)PhgLDChaDF7) bound to Saccha

216 STLs contained a peptidomimetic PAR(2) agonist (2-aminothiazol-4-yl-LIGRL

217 2) (2-f-LIGRLO-NH(2)) underscores the use of peptidomimetic PAR(2) ligands as a mechanism to enhance

218 Structure-affinity studies led to the peptidomimetic, pCinn-Haic-Gln-NHBn (21), which had an I

219 These data recommend pursuit of BH3-peptidomimetic pharmacotherapy in human synovial sarcoma

220 outes by which other tumors evade BH3-domain peptidomimetic pharmacotherapy.

221 ttractive intermediates for the synthesis of peptidomimetics, polyheterocycles, and other multifuncti

222 Most of the peptidomimetics possessed high to moderate activity towa

223 Azapeptides are peptidomimetics possessing semicarbazide residues that c

224 Here, we describe how small peptide and peptidomimetic probes derived from the lipid binding dom

225 date derivatives of TFV should be considered peptidomimetic prodrugs of TFV.

226 s an important strategy for the synthesis of peptidomimetics (pseudo-peptides).

227 tems in Lepidoptera and aid in the design of peptidomimetics, pseudopeptides or small molecules capab

228 ch to a novel class of falcipain inhibitors: peptidomimetic pyrimidine nitriles.

229 hat 6 out of all 8 possible stereoisomers of peptidomimetic pyrrolidines can be obtained in good yiel

230 Peptidomimetics represent an important field in chemistr

231 Peptides and peptidomimetics represent the middle space between small

232 Incorporation of unnatural amino acids and peptidomimetic residues into therapeutic peptides is hig

233 pha/beta, alpha/gamma and alpha/delta hybrid peptidomimetics, respectively.

234 A series of opioid analogues with a common peptidomimetic scaffold displayed remarkable inversions

235 Moreover, this peptidomimetic selectively interferes with the integrity

236 that, through N-acetylation of our original peptidomimetic series, we are able to improve DOR affini

237 In a previously described peptidomimetic series, we reported the development of bi

238 ex with PBP 5 in complex with a boronic acid peptidomimetic shows that the position corresponding to

239 nd evaluated the therapeutic efficacy of the peptidomimetic small molecule ICG-001, which specificall

240 t the poor mimicry of the amide bond by many peptidomimetics stems from their inability to partake in

241 quence-defined family of oligomers, enable a peptidomimetic strategy, especially considering the easi

242 Therefore, a new peptidomimetic strategy, referred to as fragment hopping

243 The peptidomimetic structure was synthesized by solid-phase

244 of drugs as they accept a large spectrum of peptidomimetics such as beta-lactam antibiotics, antivir

245 ptides is a means to begin accessing complex peptidomimetics systematically.

246 Thus, peptidomimetic targeting of transcription factor fusion

247 search for effective cationic antimicrobial peptidomimetics targeting specific bacteria.

248 g two additional residues and the beta-sheet peptidomimetic template "Hao".

249 MTI-101 is a first-in-class peptidomimetic that binds a CD44/ITGA4 containing comple

250 he Win motif-WDR5 interaction, we designed a peptidomimetic that binds WDR5 (Kd approximately 3 nm) a

251 gated it to an electrophilic derivative of a peptidomimetic that binds with high affinity and specifi

252 we have recently reported an imidazole-based peptidomimetic that has shown PCSK9 inhibitory activity

253 ion with new or approved beta-lactams, and a peptidomimetic that have entered full clinical developme

254 ared with cilengitide, an integrin-targeting peptidomimetic that performed poorly in recent clinical

255 Herein, we review recent developments in peptidomimetics that are formed via heteroatom replaceme

256 ionships, we developed phenylimidazole-based peptidomimetics that are highly potent for Mtb20S.

257 -AApeptides are a new class of antibacterial peptidomimetics that are not prone to antibiotic resista

258 describe Neoseptins, chemically synthesized peptidomimetics that bear no structural similarity to th

259 to focus our attention on short peptides or peptidomimetics that behave as LMWGs.

260 gn, synthesis, and evaluation of macrocyclic peptidomimetics that bind to WD repeat domain 5 (WDR5) a

261 menable to the development of small molecule peptidomimetics that could be used to modulate NER repai

262 ar weight drugs against NS3-4A are substrate peptidomimetics that have a similar binding and resistan

263 g monoclonal antibodies, fusion proteins and peptidomimetics that have been approved, that are underg

264 n order to obtain gold(III)-based anticancer peptidomimetics that might specifically target two pepti

265 he development of D-enantiomer antimicrobial peptidomimetics that target bacterial membranes of certa

266 be taken into account in designing potential peptidomimetics that target P. gingivalis adherence and

267 ibody and phage particles bearing a molinate peptidomimetic, the EI performed with an IC(50) of 0.15

268 Similar to peptides and other peptidomimetics, these well-defined synthetic macromolec

269 ssess several features that are desirable in peptidomimetics; they are easily synthesized, fold into

270 inhibitors ranging from small molecules and peptidomimetics to biologics.

271 otective antibodies may facilitate design of peptidomimetics to focus vaccine responses on protective

272 We report herein the capacity of sugar-based peptidomimetics to inhibit both Abeta1-42 early oligomer

273 present study, we designed a large number of peptidomimetics to target the MLL1/WDR5 interaction base

274 ylamido peptidomimetics and beta-turn cyclic peptidomimetics via "volatilizable" aminoalkyl functiona

275 Peptidomimetic vinyl heterocyclic inhibitors (PVHIs) con

276 ues, the binding mechanism of that imidazole peptidomimetic was predicted.

277 for the synthesis of bicyclic 2-pyridones as peptidomimetics was developed.

278 structural variation of these antibacterial peptidomimetics was investigated as a tool for optimizin

279 Taurine-containing water-soluble peptidomimetics were designed and synthesized.

280 Beta-turn cyclic peptidomimetics were generated by intramolecular S(N)Ar

281 Both the linear and the cyclic peptidomimetics were obtained with good to excellent yie

282 A series of vinyl sulfone-containing peptidomimetics were rationally designed, synthesized, a

283 The peptidomimetics were used at very low concentrations (10

284 of the inhibitors that are on the market are peptidomimetics, where a conserved water molecule mediat

285 of this Pauli repulsion by employing common peptidomimetics, wherein the n --> pi* interaction is at

286 completely new, previously unknown family of peptidomimetics, which are hydrolytically stable and dis

287 Our study led to the design of high-affinity peptidomimetics, which bind to WDR5 with K(i) < 1 nM and

288 resent a new generation of unnatural helical peptidomimetics, which have similar folding conformation

289 ysis of a novel class of heteroatom-modified peptidomimetics, which we shall call "oxyazapeptides".

290 affold was used for the preparation of model peptidomimetics, whose beta turn conformation was confir

291 characterization of this new thiazole-valine peptidomimetic will facilitate design and synthesis of a

292 , we report here for the first time a linear peptidomimetic with three triazole insertions in its bac

293 hermore, optimization of the length of these peptidomimetics with an alternating cationic-hydrophobic

294 rovided two pairs of Pro-Leu-Gly-NH(2) (PLG) peptidomimetics with contrasting dopamine receptor modul

295 The "triazole scan" yielded peptidomimetics with improved resistance to enzymatic de

296 n producing biologically functional, helical peptidomimetics with non-natural elements, increased pro

297 Peptoids constitute a class of peptidomimetics with potential as protease resistant, bi

298 ioid receptor (DOR) antagonist bicyclic core peptidomimetics with promising analgesic activity and re

299 c compounds 1b and 3b provided the first PLG peptidomimetics with the ability to decrease the binding

300 on, and conformational analysis of the first peptidomimetics with two pendant, chiral nitronyl nitrox